I-allergies shots kunye ne-allergies ehla ukunyanga kwe-eczema
I-dicatitis ephezulu isisoloko sisisimboli sokuqala sesifo esichaphazelekayo, esichaphazela kakhulu abantwana abaselula, ngokuqhelekileyo ngaphambi kweminyaka emi-5 ubudala. I-aicic dermatitis ibangelwa ukugqithiswa kokutya kunye neengxaki zokusingqongileyo (ezifana ne-pollen, i-molds, i-pet dander kunye nezidumba ezinothuli) kuma-85 ekhulwini kubantu abachaphazelekayo. Kubantwana abaninzi abane-dermatitis ye-atopic, i -rhinitis ye-allergen iza kuqala ukuphuhlisa esikolweni, kwaye abanye ba bantwana baya kuhlakulela i- asthma ngobuselula.
Le nkqubela yesifo esichaphazelekayo ibizwa ngokuthi "ukuhamba kwe-atopic" . Kuye kwaba nempumelelo ethile ekunqumeni ukuhamba kwe-atopic ngokusebenzisa ukusetyenziswa kwamachiza kunye ne- immunotherapy (i-allergy shots) .
Iinkatho ezahlukeneyo zonyango zifumanekayo kwezi zifo ezihlukeneyo, eziquka ukukhuselwa kwezinto ezivuthayo , imithi kunye nokusetyenziswa kwe-immunotherapy. I-Immunotherapy, kubandakanywa ukutshatyalaliswa kwamanzi kunye nokunyuka kwamathambo , yilezo zonyango zonyango kuphela eziguqula ingxaki engundoqo ye-allergies, kwaye yile yonyango kuphela. Kwiminyaka emininzi, i-immunotherapy isetyenziselwe unyango lwe-rhinitis ye-allergen, i-conjunctivitis ye-allergen kunye ne-asthma ye-allergen. Ngoku kutshanje, uphando oluthile lubonisa ukuba i-immunotherapy ingaba luncedo ekwenzeni unyango lwe-atopic dermatitis.
I-Allergy Shots ye-Atopic Dermatitis
Izifundo ezahlukeneyo zenzeke kwiminyaka yakutshanje ukuba zihlolisise ukuba kungenzeka ukuba ukukhwabanisa kwamanzi kunokunceda unyango lwe-atopic dermatitis.
Ininzi yalezi zifundo zibonise ukuba ukukhwabanisa kwamanzi kunceda ekunciphiseni iimpawu ze-dermatitis ze-atop (njengoko zilinganiselwe yi-SCORAD-isisityebi esincedo ekunikezeni ixabiso lentengo elisekelwe kwinani lesikhumba elibandakanyekayo, ukusuka ku-1 ukuya ku-100) kunye nokunciphisa i -steroid kufuneka ukulawula iimpawu. Izibhamu ze-allergies zazinempumelelo kakhulu ekuphatheni abantu abane-dermatitis eyingozi kakhulu, kunye nexabiso le-SCORAD elingaphezulu kwama-40, kunye nabantu abanomdaka othungelelwa ngumthunzi njenge-trigger ye-atermic dermatitis.
I-allergy Drops for Atopic Dermatitis
I-allergy drops, okanye i-immunotherapy, iquka ukuthabatha oko umntu ayenayo kwaye uyifake phantsi kolwimi. Isiphumo sichaphazela kakhulu kunye nokukhwabanisa kwendabuko-ukunciphisa izibonakaliso zokungabikho komzimba, ukunciphisa inani lemithi echasene neyonyango olufunekayo, kunye nokukwazi ukunyanga iimpawu zonyango. Ukuhlaselwa kwamanzi, ngelixa lisetyenziswe eYurophu iminyaka emininzi, kuthathwa njengophando kwi-United States ngoku, kwaye ke ke kuphela kunikwa abadlali abancinci. Efana ne-shorts, i-allergies drops iye yasetyenziselwa unyango lwe-rhinitis ye-allergen, i-conjunctivitis ye-allergen, kunye ne-asthma ye-allergen-kodwa ingaqhelekanga isetyenziselwa i-atopic dermatitis.
Izifundo ezimbalwa zihlolisise inzuzo yokuhlaselwa kwamanxuwa ekunyanga kwe-dermatitis ye-atopic, bonke abantu abanomdaka wokungcola. Uphando olupapashwe ngo-2007 lufumene ukuba ukuhlaselwa kwamanzi aqulethwe ngothuli kwaba yimpumelelo ekwenzeni unyango olunomlinganiselo wokumodareyitha we-atopic dermatitis (nge-SCORAD phakathi kwe-8 no-40). Kule qela, kukho ukuhla kweempawu ze-dermatitis ze-atopic kunye nokunciphisa inani lemithi efunekayo yokunyanga iimpawu ze-atopic dermatitis. Amanxuwa e-allergies awazange ancedise unyango lwe-atopic dermatitis enamandla (SCORAD enkulu kunama-40) obangelwa ngothuli lwamanzi.
Ukhuseleko lwe-Immunotherapy nge-Atopic Dermatitis
Ukukhwabanisa kwamanzi ngamayeza ngokuqhelekileyo unyango olukhuselekileyo nolunempumelelo lweemeko ezahlukeneyo zokugula; ngenxa yokuba kungenzeka ukuba i- anaphylaxis , nangona kunjalo, abantu abafumana i-immunotherapy kufuneka bahlolwe kwiofisi yonyango imizuzu engama-30. Ngakolunye uhlangothi, i-allergy drops, ngokuqhelekileyo, inikezelwa ekhaya, enikwe umngcipheko ophantsi kakhulu kule ndlela ye-immunotherapy eyenza i-anaphylaxis enzima.
Kwiminyaka emininzi, i-allergists ixhalabele malunga nokuba kunokwenzeka ukuba izilwanyana ezinobungozi zenze i-dermatitis engaphezulu. Oku kungenxa yokuba i-dermatitis engapheliyo ikwabelana ngezixhobo zokuxilongwa ngeempawu zokuzibulala (ezifana ne- lupus kunye ne-rheumatoid arthritis), engadlukisayo xa ikhutshwe.
Nangona uphando oluninzi lubonisa ukuba i-immunotherapy ikhuselekile kwaye isebenzayo kwi-dermatitis ye-atopic, ukuya kuma-20 ekhulwini abantu babenemiphumo embi yeempawu zabo ze-dermatitis kunye neentlobo zamanzi.
Fumana konke owake wafuna ukwazi nge- dermatitis ye-atopic .
Imithombo:
Cox L, uNelson H, Lockey R. Allergen Immunotherapy: I-Parameter yokuSebenza IsiThuseli sesithathu. J Allergy Clin Immunol. 2010;
Pajno GB, Caminiti L, Vita B, et al. I-Immunotherapy yeeNkcazo kwi-Children-Sensitized Children ne-Atopic Dermatitis: I-Randomized, Double-Blind, i-Placebo-Controlled Study. J Allergy Clin Immunol. 2007; 120: 164-70.
UBussmann C, uBockenhoff A, uHenke H, et al. Ngaba i-Allergen-Specific Immunotherapy ibonisa indlela yokwelapha yezigulane nge-Atopic Dermatitis? J Allergy Clin Immunol. 2006; 118: 1292-8.